Curriculum Vitae

PERSONAL INFORMATION Jean-Pierre Gillet

WORK EXPERIENCE

January 2001-September 2001 Research Associate Advanced Array Technology (Belgium) Elaboration of a Low Density DNA Microarray to detect Multidrug Resistance in Human Tumor by Expression Profiling of ATP-Binding Cassette Transporter Genes

May 2006-April 2011 Postdoctoral Fellow NIH-NCI (Bethesda, Maryland, USA), Laboratory of Cell Biology, Center for Cancer Research (United States) Basic and translational research

May 2011-December 2012 Staff Scientist NIH-NCI (Bethesda, Maryland, USA), Laboratory of Cell Biology, Center for Cancer Research (United States) Basic and translational research

September 2012-September 2014 Assistant Professor University of Namur, Faculty of Medicine, Department of Biomedical Sciences (Belgium) Head of Laboratory of Molecular Cancer Biology Professor of preclinical drug development, pharmacology and pharmacogenomic

September 2014-September 2015 Associate Professor University of Namur, Faculty of Medicine, Department of Biomedical Sciences (Belgium) Head of Laboratory of Molecular Cancer Biology Professor of preclinical drug development, pharmacology and pharmacogenomic

February 2014-December 2018 Director of Biomedical Sciences Programme University of Namur, Faculty of Medicine, Department of Biomedical Sciences (Belgium) Manage the program of the Bachelor and Master degrees.

September 2015-September 2018 Professor University of Namur, Faculty of Medicine, Department of Biomedical Sciences (Belgium) Head of Laboratory of Molecular Cancer Biology Professor of preclinical drug development, pharmacology and pharmacogenomic

November 2015- Present Non-Clinical Assessor Federal Agency for Medicines and Health Products (Belgium)

December 2016- Present Director of Biomedical Sciences Department University of Namur, Faculty of Medicine, Department of Biomedical Sciences (Belgium)

September 2018- Present Full Professor University of Namur, Faculty of Medicine, Department of Biomedical Sciences (Belgium) Head of Laboratory of Molecular Cancer Biology

30/12/2020 European Medicine Agency Page 1/13 Professor of preclinical drug development, pharmacology and pharmacogenomic

EDUCATION AND TRAINING

September 1999-December 1999 Erasmus Program University of Lyon (Claude Bernard) (France) Cellular Biology and Molecular Genetic courses

January 2000-June 2000 Undergraduate Thesis University of Namur (Belgium) Cloning and characterization of the human and mouse reelin promoters

September 1996-September 2000 Bachelor Degree in BBMC (Biochemistry, Molecular and Cellular Biology) University of Namur (Belgium) Biological Sciences

September 2001-April 2006 PhD in Molecular and Cellular Biology University of Namur (Belgium) Microarray-based Detection for Multidrug Resistance in Human Tumors by Expression Profiling of ABC Transporter Genes and for Small B-cell non Hodgkin's Lymphoma Characterization

September 2012-June 2013 University Certificate in Laboratory Animal Sciences (mammals, fish, amphibians) for those actively involved in experiments carried out on animals University of Namur (Belgium) corresponding to the function described in DIR/2010/63/UE carrying out procedures on animals

September 2013-June 2014 University Certificate in Laboratory Animal Sciences (mammals, fish, amphibians) for Master of experiments University of Namur (Belgium) corresponding to the function b described in DIR/2010/63/UE designing procedures and projects

ADDITIONAL INFORMATION

Expertise I am a molecular and cellular biologist who has been working for fifteen years in the field of cancer research. All my projects have been closely related to translational research and primarily related to the mechanisms governing multidrug resistance (MDR) to chemotherapeutic agents. My Ph.D. work led to the discovery of ABCA3 as a marker of poor prognosis in childhood acute myeloid leukemia. My work also contributed to suggest the implication of more than 30 ABC transporters in MDR in addition to the 3 main transporters, which are ABCB1, C1 and G2. During my postdoctoral internship, I established in the host laboratory a new analytical assay for assessing expression profiles of highly homologous gene families. This is a crucial step forward as numerous MDR mediators belong to such gene families. My investigations, based upon this assay, led to the refinement of a previously established database with the capability to more precisely identify compounds whose resistance is mediated by ABC transporters as well as ascertain which compounds are responsible for collateral sensitivity. I also highlighted two new gene signatures for MDR in ovarian cancer and hepatocellular carcinoma. My work also clearly demonstrated that established cancer cell lines have little relevance in predicting drug response in the cancers from which they are derived, strongly suggesting that new in vitro models are needed to test new strategies to circumvent drug resistance in cancer. I am currently studying the role of ABCB5 transporter in normal cells and in tumor, especially in melanoma.

30/12/2020 European Medicine Agency Page 2/13 Publications 1. PUBLICATION - RESEARCH ARTICLE * both authors contributed equally to this work. 1.Gillet JP*, Efferth T*, Steinbach D, Hamels J, de Longueville F, Bertholet V, Remacle J. Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes. Cancer Research. 2004 Dec 15; 64(24):8987-93. IF: 8.234. 2.Gillet JP*, Schneider J*, Bertholet V, de Longueville F, Remacle J, Efferth T. Microarray Expression Profiling of ABC Transporters in Human Breast Cancer. Cancer Genomics & Proteomics. 2006 Mar-Apr; 3(2):97-106. IF: NA. 3.Steinbach D*, Gillet JP*, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T. Expression Profiling of ABC-Transporters in Childhood Acute Myeloid Leukemia Reveals ABCA3 as a Possible Cause of Drug Resistance. Clinical Cancer Research. 2006 July 15; 12(14):4357-4363. IF: 7.338.

4.Efferth T*, Gillet JP*, Sauerbrey A, Zintl F, Bertholet V, de Longueville F, Remacle J, Steinbach D. Expression Profiling of ATP-Binding Cassette Transporters in Childhood Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics. 2006 Aug; 5(8):1986-94. IF: 5.225.

5.van de Ven R, Scheffer GL, Reurs AW, Lindenberg JJ, Oerlemans R, Jansen G, Gillet JP, Glasgow JN, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD. A role for Multidrug Resistance Protein 4 (MRP4; ABCC4) in Human Dendritic Cell Migration. Blood. 2008 Sep 15; 112(6):2353-9. IF: 10.558.

6.Gillet JP, Molina TJ, Jamart J, Gaulard P, Leroy K, Briere J, Theate I, Thieblemont C, Bosly A, Herin M, Hamels J, Remacle J. Evaluation of a Low Density DNA Microarray for Small B-Cell non-Hodgkins Lymphoma Differential Diagnosis. Leukemia and Lymphoma. 2009 March; 50(3):410418. IF: 2.492. 7.Orina JN, Calcagno AM, Wu CP, Varma S, Shih JH, Lin M, Eichler G, Weinstein JN, Pommier Y, Ambudkar SV, Gottesman MM, Gillet JP. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Molecular Cancer Therapeutics. 2009 Jul; 8(7):2057-66. IF: 5.225.

8.Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. Journal of the National Cancer Institute. 2010 Nov 3; 102(21):1637-52. IF: 14.697.

9.Mothanje BL, Handley M, Anu R, Gillet JP, Wu CP, De Donatis GM, Cauda R, Gottesman MM. Exposure to HIV-Protease Inhibitors Selects for Increased Expression of P-glycoprotein (ABCB1) in Kaposi´s Sarcoma Cells. British Journal of Cancer. 2011 Aug 9; 105(4):513-22. IF: 4.831. 10.Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora M, Patel C, Orina JN, Eliseeva E, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM. Redefining the Relevance of Established Cancer Cell Lines to the Study of Mechanisms of Clinical Anti-Cancer Drug Resistance. Proceedings of the National Academy of Sciences USA. 2011 Nov 15; 108(46):18708-13, and Highlights: This week in PNAS. 2011 108 (46):18567-18568. IF: 9.771. 11.Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM. Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions. Molecular Pharmaceutics. 2011 Dec 5; 8(6):2080-8. IF: 5.400. 12.Rottenberg S, Vollebergh MA, de Hoon B, de Ronde JJ, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Loden M, Sol W, van der Burg E, Wesseling J, Gillet JP,

30/12/2020 European Medicine Agency Page 3/13 Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers JJ, Borst P. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Research. 2012 May 1; 72(9):2350-61. IF: 8.234. 13.Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood A, Ambudkar S, Seiden M, Rueda B, Gottesman M. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clinical Cancer Research. 2012 Jun 1;18(11):3197-3206. IF: 7.338. 14.Shen DW, Pouliot LM, Gillet JP, Ma W, Johnson AC, Hall MD, Gottesman MM. The Transcription Factor GCF2 is an Upstream Repressor of the Small GTPAse RhoA, Regulating Membrane Protein Trafficking, Sensitivity to Doxorubicin and Resistance to Cisplatin. Molecular Pharmaceutics. 2012 Jun 4;9(6):1822-33. IF: 5.400. 15.Stordal B, Hamon M, McEneaney V, Roche S, Gillet JP, OLeary J, Gottesman MM and Clynes M. Resistance to Paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-Glycoprotein. PLoS ONE. 2012;7(7):e40717. IF: 4.411. 16.Padmanabhan R, Chen KC, Gillet JP, Handley M, Mallon BS, Hamilton RS, Park K, Varma S, Mehaffey MG, Robey PG, McKay RDG, Gottesman MM. Regulation and Expression of the ATP-binding Cassette (ABC) Transporter ABCG2 in Human Embryonic Stem Cells. Stem Cells. 2012 Oct;30(10):2175-87. IF: 7.871. 17.Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood. 2013 May 16;121(20):4115-2. IF: 9.898. 18.Patel C, Stenke L, Varma S, Lagergren Lindberg M, Björkholm M, Sjöberg J, Viktorsson K, Lewensohn R, Landgren O, Gottesman MM, Gillet JP. Multidrug resistance in relapsed AML: Evidence of biological heterogeneity. Cancer. 2013 Aug 15;119(16):3076-83. IF: 4.771. 19.Doherty B, Lawlor D, Gillet JP, Gottesman MM, O'Leary JJ, Stordal B. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells. Anticancer Research. 2014 Jan;34(1):503-7. IF: 1.713. 20.Homolya L, Fu D, Sengupta P, Jarnik M, Gillet JP, Vitale-Cross L, Gutkind JS, Lippincott-Schwartz J, Arias IM. LKB1/AMPK and PKA control ABCB11 trafficking and polarization in hepatocytes. PLoS ONE. 2014 Mar18; 9(3):e91921. IF: 4.411. 21.Keniya MV, Holmes AR, Niimi M, Lamping E, Gillet JP, Gottesman MM, Cannon RD. Drug Resistance Is Conferred on the Model Yeast Saccharomyces cerevisiae by Expression of Full-Length Melanoma-Associated Human ATP-Binding Cassette Transporter ABCB5. Mol Pharm. 2014 Oct 6;11(10):3452-62. IF: 4.570. 22.Zheng M, Zhang H, Dill DL, Clark JD, Tu S, Yablonovitch AL, Tan MH, Zhang R, Rujescu D, Wu M, Tessarollo L, Vieira W, Gottesman MM, Deng S, Eberlin LS, Zare RN, Billard JM, Gillet JP, Li JB, Peltz G. The role of abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans. PLoS Med. 2015 Feb 3;12(2):e1001782. IF:14.0. 23.Salem GH, Dennis JU, Krynitsky J, Garmendia-Cedillos M, Swaroop K, Malley JD, Pajevic S, Abuhatzira L, Bustin M, Gillet JP, Gottesman MM, Mitchell JB, Pohida TJ. SCORHE: A novel and practical approach to video monitoring of laboratory mice housed in vivarium cage racks. Behavior Research Methods. 2015 Mar;47(1):235-50. IF: 1.907. 24.Souza PS, Madigan JP, Gillet JP, Kapoor K, Ambudkar SV, Maia RC, Gottesman MM, Fung KL. Expression of the Multidrug Transporter, P-glycoprotein, and Apoptosis-Associated Endogenous TRAIL are Inversely Related. Exp Cell Res. 2015 Aug 15;336(2):318-28. IF: 3.246. 25.Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Mol Pharmacol. 2016 Feb;89(2):263-72. IF: 4.13. 26.Sana G, Madigan JP, Gartner JJ, Fourrez M, Lin CH, Qutob N, Narayan J, Shukla S, Ambudkar SV, Xia D, Rosenberg S, Gottesman MM, Samuels Y, Gillet JP. Exome sequencing of ABCB5 identifies recurrent melanoma mutations that result in increased proliferative and invasive capacities.

30/12/2020 European Medicine Agency Page 4/13 J Invest Dermatol. 2019 Sep;139(9):1985-1992.e10. IF: 6.448. 27.Bonito CA, Ferreira RJ, Ferreira MJU, Gillet JP, Cordeiro NMDS, dos Santos DJVA. Theoretical insights on helix repacking as the origin of P-glycoprotein promiscuity. Scientific Reports. 2020 Jun 17;10(1):9823. IF: 3.998. 2. PUBLICATION - REVIEW ARTICLE 2.1. Guest editor Issue in Drug Resistance Updates entitled: Overcoming Multidrug Resistance in Cancer: 35 years after the discovery of ABCB1. 2012 Feb; 15(1-2):2-4. Guest Editors: Jean-Pierre Gillet & Michael M. Gottesman. Feb; 15(1-2). IF: 12.312. 2.2. Review manuscript 1.Gillet JP, de Longueville F, Remacle J. DualChip Microarray as a New Diagnostic Tool in Cancer Research. Expert Review of Molecular Diagnostics. 2006 May; 6(3):295-306. IF: 4.652. 2.Gillet JP, Efferth T, Remacle J. Chemotherapy-Induced Resistance by ATP-Binding Cassette Transporter Genes. Biochimica Biophysica Acta-Reviews on Cancer. 2007 Jun; 1775(2):237-62. IF: 9.886. 3.Chen KG, Valencia JC, Gillet JP, Hearing VJ, Gottesman MM. Involvement of ABC Transporters in Melanogenesis and the Development of Multidrug Resistance of Melanoma. Pigment Cell Melanoma Research. 2009 Dec; 22(6):740-9. IF: 4.750. 4.Gillet JP and Gottesman MM. Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer. Special issue for Current Pharmaceutical Biotechnology. 2011 Apr; 12(4):686-92. IF: 3.455.

5.Shaffer B, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: Still a Daunting Challenge to the Successful Treatment of AML. Drug Resistance Updates. 2012 Feb; 15(1-2):62-9. IF: 12.312. 6.Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a Better Understanding of the Complexity of Cancer Drug Resistance. Annu Rev Pharmacol Toxicol. 2016;56:85-102. IF: 18.365. 2.3. Book chapter 1.Gillet JP, Kimchi-Sarfaty C, Shinar S, Licht T, Lee C, Hafkemeyer P, Hrycyna CA, Pastan I, Gottesman MM. Selectable Markers for Gene Therapy. In Gene and Cell Therapy, 3rd Edition, Nancy Smyth Templeton (Ed.), Marcel Dekker Inc.: New York, USA, 2008, 555-580. 2.Gillet JP, Macadangdang B, Fathke RL, Gottesman MM, Kimchi-Sarfaty C. The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases such as Cancer. In Cancer Gene Therapy, 2nd Edition, Wolfgang Walther, Ulrike Stein (Eds.), Humana Press, Totowa, NJ, USA, 2009, 5-54. (Methods in Molecular Biology, 542). 3.Gillet JP, Okabe M, Gottesman MM. The Hepatocyte and the Cancer Cell: Dr. Jekyll and Mr. Hyde. In The liver: Biology and Pathobiology, 5th Edition, Irwin M. Arias, Nelson Fausto, James L. Boyer, Francis V. Chisari, David A. Shafritz (Eds.), Wiley-Blackwell, Oxford, England, 2009, 1075-1090. 4.Gillet JP and Gottesman MM. Mechanisms of multidrug resistance in cancer. In MultiDrug Resistance in Cancer, Jun Zhou (Ed). Humana Press, Totowa, NJ, USA, 2010, 47-76. (Methods in Molecular Biology, 596). 5.Gillet JP, Hunt RC, Kimchi-Sarfaty C, Kafri T, Zou J, Rao M, Gottesman MM. Selectable Markers for Gene Therapy. In Gene and Cell Therapy, 4th Edition, Nancy Smyth Templeton (Ed.), Marcel Dekker Inc.: New York, USA, 2015, 701-740. 6.Gillet JP, Boonen M, Jadot M, Gottesman MM. The Dual Role of ABC Transporters in Drug Metabolism and Resistance to Chemotherapy. In The liver: Biology and Pathobiology, 6th Edition, Irwin M. Arias, Harvey Alter, James L. Boyer, David Cohen, Snorri Thorgeirsson, David A. Shafritz and Allan Wolkoff (Eds.), Wiley-Blackwell, Oxford, England, 2020. 3. PUBLICATION - BOOK REVIEW Gillet JP. Gene expression profiling by microarrays clinical implications. W-K Hofmann (Editor) Publisher: Cambridge University Press, 2006. ISBN: 0521853966. British Journal of Cancer. 2007 96: 401.

30/12/2020 European Medicine Agency Page 5/13 4. PUBLICATION - RESEARCH HIGHLIGHT Gillet JP, Gottesman MM. Identification of gene signatures involved in the mechanisms of multidrug resistance. Personalized Medicine. 2009 6(2), 133-134. 5. PUBLICATION - COMMENTARY Gillet JP, Varma S, Gottesman MM. The Clinical Relevance of Cancer Cell Lines. Journal of the National Cancer Institute. 2013 Apr 3;105(7):452-8. IF: 14.697.

Projects PATENTS / EMPLOYEE INVENTION REPORT US 10/748,713. 30 December 2003 EP 04030895.9. 28 December 2004 Applicants: Remacle J, Gillet JP, Efferth T. A Method for Quantitative Determination of Multi-Drug Resistance in Tumors.

US 61/308,946. February 27, 2010 Applicants: Gillet JP, Calcagno AM, Varma S, Davidson B, Ganapathi R, Sood A, Ambudkar S, Seiden M, Rueda B and Gottesman M. Methods for prediction of clinical outcome to treatment of ovarian cancer patients. OFFICIAL DUTIES King Baudoin Foundation. Jury member for the Fund Simon Bauvin, the Fund Christian Lispet, the Fund Robert Brancart and the Fund Denise Raes created to support medical scientific research into childhood cancer in the French Community of Belgium. FRIA (Fund for Research Training in Industry and Agriculture). Jury member 2016-2021.

Memberships AWARDS & GRANTS 2012: US Federal Technology Transfer Award 2012: NIH Merit Bonus Cash Award 2010: US Federal Technology Transfer Award 2010: NCI Directors 2010 Intramural Career Development Innovation Award 2009: NIH Exceptional Pay Increase Award 2008: FEBS Youth Travel Fund (YTF) grant 2006-2011: Postdoctoral visiting fellowship, National Institutes of Health (Bethesda, MD, USA) 2005: Award winner of the Cycle for Life Fund (Roche Oncology, Belgium) 2005: Award winner of the Adrien Bauchau Fund for young researcher (University of Namur, Belgium) 2004-2005: Eppendorf Array Technologies research grant (Namur, Belgium) 2001-2003: Pathology and Molecular Onco-Hematology research grant (IPG, Loverval, Belgium) 1999: Erasmus European mobility grant (University of Lyon, France) MEMBER OF SCIENTIFIC SOCIETY 2002-present: European Association for Cancer Research 2007-present: American Association for Cancer Research 2008-present: Belgian Society of Biochemistry and Molecular Biology 2016-present: American Society for Clinical Pharmacology and Therapeutics 2007-2011: American Society of Hematology EDITORIAL ACTIVITIES Reviewer for: FEBS, Planta Medica, Cellular and Molecular Life Sciences, PLoS ONE, Journal of National Cancer Institute, BBA - Molecular Basis of Disease, Biochemical Pharmacology, etc. ORAL PRESENTATION 1.2nd Annual North American ABC Genetic Workshop 2005, Frederick, Maryland, USA, September 29-30. Expression profiling of ABC-transporters in leukemic children identifies two gene candidates (ABCA2 & ABCA3) involved in chemotherapy-induced resistance.

30/12/2020 European Medicine Agency Page 6/13 2.10th World Congress on Advances in Oncology and 8th International Symposium on Molecular Medicine 2005, Hersonissos, Crete, October 13-15. Low Density DNA Microarray as New Routine Tool for Diagnosis in Hematological Malignancies. 3.4th Annual North American ABC Genetic Workshop 2007, Frederick, Maryland, USA, October 04-05. Gene expression profiling of multidrug resistance mechanisms in ovarian cancer using TaqMan Low Density Arrays. 4.5th Annual North American ABC Genetic Workshop 2008, Frederick, Maryland, USA, September 24-26. ABCB5, a poorly characterized ABC transporter highly expressed in Melanoma. 5.Gordon Research Conference 2009, Galveston, TX, March 22-27. Multi-Drug Efflux Systems. The characterization of ABCB5 reveals a full length transporter mediating multidrug resistance 6.AACR annual meeting 2009, Denver, CO, April 18-22. Characterization of ABCB5, a poorly studied ABC transporter highly expressed in melanomas. 7.6th Annual North American ABC Genetic Workshop 2009, Frederick, Maryland, USA, September 24-25. Multifactorial multidrug resistance correlates with overall survival in ovarian primary serous carcinoma. 8.8th Annual North American ABC Genetic Workshop 2011, Frederick, Maryland, USA, September 28-29. Functional studies on ABCB5: a pleiotropic phenotype in knock-out mice of this multidrug transporter. 9.9th Annual North American ABC Genetic Workshop 2012, Frederick, Maryland, USA, September 27-28. Multidrug Resistance in Relapsed AML: Evidence of Biological Heterogeneity. 10.Gordon Research Conference 2013, Ventura, CA, March 22-27. Multi-Drug Efflux Systems-Shared Molecular Mechanisms but Diverging Roles in Physiology and Medicine. ABCB5: a polyspecific efflux transporter localized to the mitochondria that doubles as a melanoma tumor suppressor gene. 11.13rd French-Belgian Annual ABC meeting 2013, Paris, France, October 18. Molecular and functional characterization of the ABCB5 transporter: a potential new tumor suppressor in melanoma. 12.Symposium NARILIS From the molecule to the drug 2015, CHU Dinant Godinne, Belgium, February 21. Study of the mechanisms of drug resistance in cancer: From ABC transporters to gene signatures. 13.NARILIS (NAmur Research Institute for LIfe Sciences) Symposium 2016, CHU-UCL Namur, Belgium, April 23. Melanoma-initiating cells and drug resistance: Study of ABCB5, a potential new tumor suppressor in melanoma 14.Celebrating 30 Years of Research on Multidrug Resistance and ABC Transporters Symposium 2016, NIH-NCI, Bethesda, MD, USA, September 22-23. The multifaceted ABCB5 transporter: spotlight on its role in tumorigenesis. 15.21th World Congress on Advances in Oncology and 19th International Symposium on Molecular Medicine 2016, Athens, Greece, October 06-08. The multifaceted ABCB5 transporter: spotlight on its role in tumorigenesis 16.NARILIS (NAmur Research Institute for LIfe Sciences) Cancer Research Pole, March 24-25, 2017. Sensitization of multidrug resistant cancers: the example of hepatocellular carcinoma. Kick-off meeting. INVITATION FOR ORAL PRESENTATION 1.The Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, November 05, 2013. Molecular and functional characterization of the ABCB5 transporter: a potential new tumor suppressor in melanoma. Invited by Professor Munir Pirmohamed (David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics, Head of Department of Molecular and Clinical Pharmacology). 2.Institute of Molecular Biology and Medicine, Université Libre de Bruxelles, February 02, 2016. Molecular and functional characterization of the ABCB5 transporter: a potential new tumor suppressor in melanoma. Invited by Professor Muriel Moser (Dean Faculty of Sciences). 3.CHU UCL Namur (Sainte-Elizabeth Site), February 10, 2016. Study of the mechanisms of drug resistance in cancer: From ABC transporters to gene signatures. Invited by Dr. Jean-François

30/12/2020 European Medicine Agency Page 7/13 Daisne (Radiotherapy Oncology Group, Chief). 4.Life Sciences Institute (ISV), UCLouvain, May 12, 2017. The Multifaceted ABCB5 Transporter: Spotlight on Its Role in Tumorigenesis. Invited by Professor Marc Boutry (Physiological Biochemistry Unit). 5.Sixième journée Coordinateurs de soins en oncologie / oncocoaches (Coordination des soins en oncologie), Juin 15, 2018. La résistance au traitement : de quoi sagit-il ? Quelle communication vers le patient ? 6.EORTC BCG Meeting, September 13-14, 2019. Leuven, Belgium. Study of the mechanisms of cancer cell resistance to conventional chemotherapy.

POSTERS 1.46th ASH Annual Meeting (American Society of Hematology) 2004, San Diego, California, USA, December 4-7. Steinbach D*, Gillet JP*, Sauerbrey A, Gruhn B, Dawczynski K, de Longueville F, Bertholet V, Zintl F, Remacle J and Efferth T, (Intr. By Sayer HG). Expression Profiling of ABC-Transporters in Childhood AML Reveals ABCA3 as a Potential Cause of Drug Resistance. 2.28th GSCB (German Society for Cellular Biology) 2005, Heidelberg, Germany, March 16-19. Efferth T*, Gillet JP*, Steinbach D, Sauerbrey A, Gruhn B, Dawzcynski K, de Longueville F, Bertholet V, Zintl F and Remacle J. Expression Profiling of ATP-Binding Cassette (ABC) Transporter Genes by a Low Density Microarray to Detect Drug Resistance of Tumors. 3.Summer Research Program Student Poster Day 2007, Bethesda, Maryland, USA, August. Harvey BA, Jr., Gillet JP and Gottesman MM. ABCA3: does this transporter play a role in multidrug resistance? 4.20th NIH Research Festival 2007, Bethesda, Maryland, USA, September 25-28. Gillet JP, Calcagno AM, Ambudkar SV and Gottesman MM. Multidrug Resistance Mechanisms Analysis in Ovarian Cancer by Gene Expression Profiling Using TaqMan Low Density Array. 5.2nd FEBS Special Meeting: ATP-Binding Cassette Proteins: From Multidrug Resistance to Genetic Disease 2008, Innsbruck, Austria, March 1-8. Gillet JP, Calcagno AM, Shih JH, Okabe M, Hall MD, Shen DW, Ambudkar SV and Gottesman MM. MDR-linked gene expression profiling in clinical ovarian tumors. 6.AACR annual meeting 2008, San Diego, California, USA, April 12-16. Gillet JP, Calcagno AM, Shih JH, Okabe M, Hall MD, Shen DW, Ambudkar SV and Gottesman MM. Analysis of multidrug resistance mechanisms in ovarian cancer. 7.Summer Research Program Student Poster Day 2008, Bethesda, Maryland, USA, August. Eliseeva T, Gillet JP, Rosenberg SA and Gottesman MM. Gene Expression Profiling of 384 MDR-Linked Genes in Metastatic Melanoma. 8.Molecular Targets Faculty Retreat 2008, Bethesda, Maryland, USA, August 12. Gillet JP, Orina JN, Calcagno AM, Wu CP, Varma S, Lin M, Vora M, Shih JH, Eichler G, Weinstein JN, Ambudkar SV and Gottesman MM. Identification of multi-drug resistance mechanisms in the NCI-60 cell lines using Taqman Low Density Array and its evaluation as a diagnostic tool for the clinical setting. 9.21st NIH Research Festival 2008, Bethesda, Maryland, USA, October 14-17. Gillet JP, Calcagno AM, Shih JH, Okabe M, Hall MD, Shen DW, Ambudkar SV and Gottesman MM. Identification of multidrug resistance gene signatures associated with overall patient survival in ovarian cancer. 10.NCI Intramural PIs retreat 2009, Bethesda, Maryland, USA, January 06. Gottesman MM, Hall MD, Liang XJ, Chen KG, Okabe M, Gillet JP and Shen DW. Unraveling the complexities of resistance to cisplatin. 11.Gordon Research Conference 2009, Galveston, Texas, USA, March 22-27. Gillet JP, Rutledge R, Wu CP, Eliseeva T, Chen KG, Fitzgerald PC, Fales HM, Xia D, Ambudkar SV and Gottesman MM. The characterization of ABCB5 reveals a full length transporter mediating multidrug resistance. 12.AACR annual meeting 2009, Denver, Colorado, USA, April 18-22. Green LJ, Gillet JP, Calcagno AM, Samuel M, Hall MD, Varma S, Shih JH, Ambudkar SV and Gottesman MM. Identification of a 3D-model which best emulates clinical epithelial ovarian cancer multi-drug resistance profiles. 13.AACR annual meeting 2009, Denver, Colorado, USA, April 18-22. Vora M, Calcagno AM, Ambudkar SV, Gottesman MM and Gillet JP. Characterization of Multidrug Resistance-linked Gene

30/12/2020 European Medicine Agency Page 8/13 Signatures from TaqMan Low Density Arrays, Microarray Gene Expression and Cellular Assays for the NCI-60 panel using an Integrative Data Analysis System, SIMUSITETM. 14.22nd NIH Research Festival 2009, Bethesda, Maryland, USA, October 06-09. Gillet JP, Rutledge R, Wu CP, Eliseeva T, Chen K, Fitzgerald P, Fales H, Xia D, Ambudkar S and Gottesman M. The characterization of ABCB5 reveals a full length transporter mediating multidrug resistance 15.Society for Melanoma Research, International Congress 2009, Boston, Massachusetts, USA, November 01-04. Gillet JP, Rutledge R, Wu CP, Eliseeva T, Chen K, Fitzgerald PC, Fales HM, Xia D, Ambudkar SV and Gottesman MM. The characterization of ABCB5 reveals a full length transporter mediating multidrug resistance. 16.3rd FEBS Special Meeting: ATP-Binding Cassette Proteins: From Multidrug Resistance to Genetic Disease 2010, Innsbruck, Austria, February 27 - March 05. Stordal B, Clynes M, Gottesman MM and Gillet JP. Mechanisms of cross resistance between cisplatin and paclitaxel in IGROV-1CDDP ovarian cancer cells. 17.3rd FEBS Special Meeting: ATP-Binding Cassette Proteins: From Multidrug Resistance to Genetic Disease 2010, Innsbruck, Austria, February 27 - March 05. Gottesman MM, Hall MD, Fung KL, Handley M and Gillet JP. What have we learned about multidrug resistance in cancer? 18.AACR annual meeting 2010, Washington, DC, USA, April 17-21. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau M, Gottesman MM, Varticovski L, Ambudkar SV. Cancer stem cell characteristics exhibited by doxorubicin-selected drug-resistant breast cancer cells. 19.AACR annual meeting 2010, Washington, DC, USA, April 17-21. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Sood AK, Ambudkar SV, Seiden MV, Rueda BR and Gottesman MM. Correlation of expression of MDR-associated genes with outcome in primary ovarian serous carcinoma. 20.23rd NIH Research Festival 2010, Bethesda, Maryland, USA, October 05-08. Gillet JP, Varma S, Gottesman MM. Characterization of ABCB5 Transcript Variants Using NextGen Sequencing. 21.52nd ASH Annual Meeting 2010, Orlando, Florida, USA, December 4-7. Patel C, Gillet JP, Stenke L, Lindberg M, Bjorkholm M, Sjoberg J, Viktorsson K, Lewensohn R, Landgren O, and Gottesman MM. Individualized Multidrug Resistance In Acute Myeloid Leukemia 22.NCI Intramural PIs retreat 2011, Bethesda, Maryland, USA, January 06. Gottesman MM, Varma S, and Gillet JP. Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma; Failure of Cell Culture Models to Reflect Clinical MDR Gene Expression Patterns.

23.ASBMB annual meeting 2011, Washington, DC, USA, April 9-13. Gottesman MM, Hall MD, Handley M, Goldsborough AS, Fung KL, Gillet JP. What have we learned about multidrug resistance in cancer? 24.AACR-NCI Conference on Systems Biology: Confronting the Complexity of Cancer 2011, San Diego, California, USA, February 27-March 2. Gillet JP, Andersen JB, Varma S, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. Multidrug resistance gene signature in hepatocellular carcinoma with poor survival allows prediction of compounds able to convert gene expression profile to one associated with good overall survival. 25.AACR-NCI Conference on Systems Biology: Confronting the Complexity of Cancer 2011, San Diego, California, USA, February 27-March 2. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AP, Sood AK, Ambudkar SV, Seiden MV, Rueda BR and Gottesman MM. Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma, but Cell Culture Models Failed to Reflect Clinical MDR Gene Expression Patterns 26.IACR Annual Meeting 2011, Dublin, Ireland, March 03-04. Stordal B, Gillet JP, Hamon M, Roche S, Keenan J, Eustace A, Ganapathi R, Sood A, Rueda B, Gottesman MM and Clynes M. Cross resistance to paclitaxel in a cisplatin-resistant ovarian cell line IS mediated by P-glycoprotein 27.24th NIH Research Festival 2011, Bethesda, Maryland, USA, October 26-28. Salem G, Dennis JU, Abuhatzira L, Gillet JP, Shanir A, Garmendia M, Swaroop K, Krynitsky J, Bustin M, Gottesman MM, Mitchell JB, Pohida TJ. Mouse activity monitoring system: A novel and practical approach to

30/12/2020 European Medicine Agency Page 9/13 in-rack home-cage laboratory mice monitoring. 28.4th FEBS Special Meeting: ATP-Binding Cassette Proteins: From Multidrug Resistance to Genetic Disease 2012, Innsbruck, Austria, March 03-March 09. Holmes AR, Keniya MV, Niimi M, Lamping E, Gillet JP, Gottesman MM and Cannon RD. Expression of full-length human ABC transporter ABCB5 confers a drug efflux phenotype on the model yeast Saccharomyces cerevisiae. 29.4th FEBS Special Meeting: ATP-Binding Cassette Proteins: From Multidrug Resistance to Genetic Disease 2012, Innsbruck, Austria, March 03-March 09. Braker PJ, Gillet JP, Gottesman MM, Beach DH, Bishop CL, Linton KJ. ABCB5 and the effect of its expression on the tumour suppressor gene p16INK4a. 30.8th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat 2012, Bethesda, Maryland, USA, April 17. Gillet JP, Andersen JB, Varma S, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. New strategy to reverse MDR tumors: study of hepatocellular carcinoma. 31.Gordon Research Conference 2012, Easton, Massachusetts, USA, July 29 - August 3. Gillet JP, Andersen JB, Varma S, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. New strategy to reverse MDR tumors: study of hepatocellular carcinoma. 32.25th NIH Research Festival 2012, Bethesda, Maryland, USA, October 09-12. Salem G, Dennis J, Gillet JP, Furusawa T, Bustin M, Gottesman MM, Mitchell JB, Pohida TJ. Automated Video-Based Assessment of Behavior for Solitary Housed Mice in a Home-Cage Environment. 33.25th NIH Research Festival 2012, Bethesda, Maryland, USA, October 09-12. Gillet JP, Vieira W, Tessarollo L, Gottesman MM. Functional studies on the multidrug transporter ABCB5: a pleiotropic phenotype in knock-out mice. 34.NCI Intramural PIs retreat 2013, Bethesda, Maryland, USA. Gillet JP, Andersen JB, Madigan JP, Varma S, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. Multidrug resistance transcriptome analysis highlights compounds that sensitize resistant hepatocellular carcinoma through increased histone acetylation. 35.AACR annual meeting 2013, Washington, DC, USA, April 06-10. Gillet JP, Andersen JB, Madigan JP, Varma S, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. Multidrug resistance transcriptome analysis highlights compounds that sensitize resistant hepatocellular carcinoma through increased histone acetylation. 36.64th AALAS National Meeting 2013, Baltimore, MD, USA, October 27-31. Salem G, Krynitsky J, Garmendia-Cedillos M, Dennis JU, Gillet JP, Gottesman MM, Furusawa T, Deng T, Bustin M, Pajevic S, Malley J, Sowers A, Mitchell JB, Pohida TJ. SCORHE: A System for Automated Video-Based Assessment of Activity and Behavior for Mice Housed in a Home-Cage Environment. 37.Society for Melanoma Research, International Congress 2014, Zurich, Switzerland, November 13-16. Gillet JP, Madigan JP, Gartner JJ, Arafeh R, Billard JM, Brunin E, Lin JC, Samuels Y, Gottesman MM. Exome sequencing of ABCB5 identifies recurrent mutations that results in increased melanoma cell proliferative and invasive capacities. 38.Symposium NARILIS From the molecule to the drug 2015, CHU Dinant Godinne, Belgium, February 21. Molecular and functional characterization of the multidrug transporter ABCB5: a potential biomarker of melanoma-initiating cells. Billard JM, Sana G, Fourrez M, Wu M, Peltz G, Gillet JP. 39.NARILIS (NAmur Research Institute for LIfe Sciences) Cancer Research Pole, March 24-25, 2017. Kick-off meeting. Sensitization of multidrug resistant cancers: the example of hepatocellular carcinoma. Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. 40.NARILIS (NAmur Research Institute for LIfe Sciences) Cancer Research Pole, March 24-25, 2017. Sensitization of multidrug resistant cancers: the example of hepatocellular carcinoma. Kick-off meeting. Sana G, Madiagan JP, Gartner JJ, Lin CH, Fourrez M, Shukla S, Ambudkar SV, Rutledge RM, Xia D, Rosenberg SV, Gottesman MM, Samuels Y, Gillet JP. 41.AACR annual meeting 2018, Chicago, IL, USA, April 14-18. Oxidative stress and protein carbonylation towards multi-drug resistance in cancer Aryal B, Gillet JP, Rao AV.

30/12/2020 European Medicine Agency Page 10/13 Other Relevant Information TEACHING EXPERIENCE USA Demystifying Medicine. Hepatocellular Cancer: A Global Disease. New Strategy to Reverse Multidrug Resistance in Tumors: Study of Hepatocellular Carcinoma. 2012 Laser Capture Microdissection Class --- BIOTRAC 29 (FAES: Foundation for Advanced Education in the Sciences): TaqMan-based RT-qPCR Analysis of Microdissected Samples. 2010 to 2012 BELGIUM Preclinical Drug Development (Approches expérimentales préclinique). Master I in Biomedical Sciences (30h lecture & 30h practice), MSBM-M102, ECTS 6. 2012 to present Laboratory Research Training (TP intégrés - laboratoire de recherche). Master I in Biomedical Sciences (8h lecture & 32h practice), MSBM-M105, ECTS 3. 2012 to present Biotechnology: principles and scale-up (Biotechnologie: principes et production). Master I in Biomedical Sciences (20h lecture & 30h practice), MSBM-M107, ECTS 4. 2012 to present Pharmacology (Eléments de pharmacologie générale). Bachelor 3rd year in Biomedical Sciences (24h lecture & 8h practice), MMED-B334, ECTS 3. 2013 to present Pharmacogenomic. Master II in Biomedical Sciences (6h lecture), MSBM M206, ECTS 2. 2013 to present Project management: Development of New Biomarkers. Master II in Biomedical Sciences (15h lecture), MSBM M207, ECTS 2. 2013 to present Cancer Cell Biology. Bachelor 3rd year in Medicine (3h lecture), MBIM B350, ECTS 4. 2014 to present Biology (Biologie Générale). Bachelor 1st year in Biomedical Sciences (35h lecture), MBIO B100, ECTS 10. 2015 to 2016 Biology (Biologie des organismes). Bachelor 1st year in Biomedical Sciences (35h lecture), SBIO B153, ECTS 4. 2016 to present Biology (Application pratique de la biologie des organismes). Bachelor 1st year in Biomedical Sciences (20h practicals), SBIO B154, ECTS 2. 2016 to present Jury Member for PhD Thesis 2017. Julie Candiracci: Feedback controls between TORC1/2 signaling pathways and tRNA modification by Elongator in Scizosaccharomyces pombe. Chair. 2016. Evelyne De Vuyst: Barrier alterations in a reconstructed human epidermis as a model for atopic dermatitis. 2014. Marie Genin: Modulation of cancer cell response to etoposide in normoxia or hypoxia by M1- or M2-polarized macrophages. Chair. 2013. Annick Notte: Study of the role of autophagy and UPR response in cancer cell resistance to Paclitaxel-induced apoptosis. MENTORING EXPERIENCE YEAR 2018 Master Thesis in Biomedical Sciences. Emilie Guérit, University of Namur. Study of the heterodimerization of ABCB5 with ABCB6 and ABCB9 by FRET. Master Thesis in Biomedical Sciences. Louise Gérard, University of Namur. Expression of ABCB5 transporters in High Five insect cells to characterize the kinetics of their ATPase activity and to identify some of their physiological substrates. Professional Internship DUT Génie Biologique option analyses biologiques et biochimiques. Camille Perdrau, IUT Lyon 1, University Claude Bernard. Construction of fluorescence resonance energy transfer vectors to study the ABCB5-ABCB6 and ABCB5-ABCB9 heterodimers. YEAR 2017 Master Thesis in Biomedical Sciences. Simon Lefèvre, University of Namur. Expression of ABCB5 transporters in High Five insect cells to characterize the kinetics of their ATPase activity and to identify some of their physiological substrates. YEAR 2016 Master Thesis in Molecular and Cellular Biology. Romy Collet, University of Namur. Development of

30/12/2020 European Medicine Agency Page 11/13 experimental in vitro models and validation of anti-ABCB5 antibodies to further characterize the expression of ABCB5 protein in the cell. YEAR 2015 Master Thesis in Molecular and Cellular Biology. Lucie Poncin, University of Namur. Study of the role of ABCB5 as a marker of melanoma-initiating cells and its expression in the mouse. Master Thesis in Molecular and Cellular Biology. Caroline Martinet, University of Namur. Subcellular localization of ABCB5 transporter and study of its role as tumor suppressor in melanoma. Bachelor Thesis in Biomedical Sciences. Franck Konchechou, HELHa, ISC Fleurus. Study of transcriptional regulation of Abc transporters in response to Abcb5 gene silencing in the mouse. YEAR 2014 Master Thesis in Molecular and Cellular Biology. Emilie Brunin, University of Namur. Characterization of the promoter region of ABCB5 gene and its regulatory pathway and localization of the ABCB5 protein in the cell. Master Thesis in Biomedical Sciences. Adeline Wannez, University of Namur. Characterization of ABCB5-IRESeGFP Knock-in mice and generation of two mouse models that express ABCB5 IRESeGFP and spontaneously develop melanoma. YEAR 2013 Internship. Guillaume Istasse, University of Louvain. Clonage de la région promotrice du gène ABCB5 dans le vecteur pGL4.10 encodant le gène rapporteur luciférase. YEAR 2012 Cancer Research Training Award (CRTA). Ms. Shree Bose from Harvard University, Massachusetts. May 2012-August 2012. Cellular localization of the ATP-binding cassette transporter ABCB5 in melanoma cell lines and its potential role as a mitochondrial transporter. YEAR 2010 Postbaccalaureate cancer research training award program (CRTA). Ms. Rita Anu from Prince Georges Community College, Maryland. September 2010-May 2010. Identification of the ABC transporters responsible for the multidrug resistance phenotype in Kaposi´s Sarcoma (SLK) cells treated with HIV-Protease Inhibitors alone or in combination with doxorubicin. Community College Summer Enrichment Program (CCSEP). Ms. Rita Anu from Prince Georges Community College, Maryland. June 2010-August 2010. Identification and characterization of ABCB5 substrates. YEAR 2009 Howard Hughes Medical Institutes Research Scholars Program (HHMI). Mr. Chirayu Patel from Brown University, Rhode Island. September 2009-June 2010. Study of multidrug resistance mechanisms in acute myeloid leukaemia. Introduction to Cancer Research Careers (ICRC). Mr. Miguel Marino from Harvard University, Massachusetts. May 2009-August 2009. Statistical framework for the analysis of high-throughput TaqMan-based qRT-PCR Data: Identifying differentially expressed genes between tissue types and assessing their usefulness in the prediction of multidrug resistance in clinical cancer samples. Cancer Research Training Award (CRTA). Mr. Vineet Singal from Stanford University, California. May 2009-August 2009. Characterization of ABCB5, a poorly studied ABC transporter highly expressed in melanomas. YEAR 2008 Clinical Research Training Program (CRTP). Ms. Lisa J. Green from Maryland University, Maryland. August 2008-June 2009. Analysis of multidrug resistance mechanisms in ovarian cancer by gene expression profiling using Taqman low density array. Summer Internship Programs (SIP). Ms. Tatiana Eliseeva from George Washington University, Maryland. June 2008-August 2008. Gene Expression Profiling of 384 MDR-Linked Genes in Metastatic Melanoma. YEAR 2007 Howard Hughes Medical Institutes Research Scholars Program (HHMI). Mr. Josiah Orina from Emery College, Atlanta, Georgia. September 2007-June 2008. Identification of multi-drug resistance mechanisms in the NCI-60 cell

30/12/2020 European Medicine Agency Page 12/13 lines using Taqman Low Density Array and its evaluation as a diagnostic tool for clinical setting.

Cancer Research Interns in Residence (CRIR). Mr. Barrington A. Harvey Jr. from Morehouse College, Atlanta, Georgia. May 2007-August 2007. ABCA3: does this transporter play a role in MDR? Poster presented in NIH Summer Intern Poster Day. Summer Internship Programs (SIP). Ms. Tatiana Eliseeva from Cambridge University, UK. July 2007-September 2007. Expression study of 4 ABCB5 transcripts encoding a full ABC transporter, two intermediate forms and a true half transporter to determine their functionality and their potential implication in drug resistance.

30/12/2020 European Medicine Agency Page 13/13